This is a working overview of GHRH analog, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-14 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Amino acid length | 44 residues | Matches the native peptide backbone |
| Molecular weight | Approximately 5135 Da | Calculated from the peptide sequence |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
| Primary studied use | Visceral fat reduction | Investigated in HIV-associated lipodystrophy |
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Derek Malcolm of the Evening Standard felt that the movie was a "dim reworking of Fatal Attraction" and noted: "Larter as the pathological minx is the best thing about it." Obsessed opened No. 1 in its opening weekend with $28 million, and making a total domestic gross of $68 million, becoming Larter's second highest-grossing film in North-America. Larter was nominated for a third time for a Teen Choice Award when she and Beyoncé were nominated for the Teen Choice Award for Choice Movie: Rumble at the 2009 Teen Choice Awards and an MTV Movie Award for Best Fight both for Obsessed. Larter reprised her role of Claire Redfield in Resident Evil: Afterlife (2010), which was filmed in 3D and saw her character ambushed and mentally manipulated by the fictional Umbrella Corporation, before she is rescued by Alice (Milla Jovovich). Like the previous Resident Evil entries, the film received negative reviews but became a major commercial success, earning $296 million worldwide. On returning to the role of Claire, Larter told JoBlo.com: "I guess people liked me as her... I'm excited that they brought me back... to work with the man [Paul W. S. Anderson] who really created this world and this vision was what excited me about joining this next installment". In 2010, Larter appeared as the title character in a short film for Absolut Vodka entitled "Lemon Drop". After the release of Afterlife, Larter went on hiatus to focus on her family.
=== Acquisition and expansion (2017–2025) === In late July 2017, the Chinese Room's directors, Dan Pinchbeck and Jessica Curry, laid off the entire staff—at that point eight people—and ditched their Brighton office for home. They cited the lack of ability to pay their staff during the interim between projects as the reason for the closure, and expressed their intentions that the studio itself was still running without the development team, with Pinchbeck and Curry working on prototyping and acquiring funds on their own time. The company released a VR game, So Let Us Melt, for Google Daydream in September, which was the final project of the former studio. At the time, Pinchbeck, Curry, and Andrew Crawshaw were working alone on the studio's next project, 13th Interior, which was to push away from the "walking simulator" model the studio had been known for. In August 2018, Sumo Group, the parent company of Sumo Digital, acquired the Chinese Room for £2.2 million, making it the fourth UK-based studio under Sumo Digital. Co-founder Pinchbeck took the role of creative director for the Chinese Room, while Curry continued as an independent composer for the studio. Pinchbeck described the acquisition as "the end of a chapter" for the studio as they determined their next project. From late summer 2018, the Chinese Room began re-staffing, adding veteran developers Ed Daly as studio director and John McCormack as art director. Dear Esther launched on iOS on 30 September 2019. On 12 June 2020 the Chinese Room released its first Apple Arcade game, Little Orpheus, to positive reviews.
=== Stops and searches === A 2015 report conducted by the US Department of Justice found that black drivers in Ferguson, Missouri, were over twice as likely to be searched during vehicle stops but were found in possession of contraband 26% less often than white drivers. A 2016 report conducted by the San Francisco District Attorney's Office concluded that racial disparities exist regarding stops, searches, and arrests by the San Francisco Police Department and that the disparities were especially salient for the black population. Blacks made up almost 42% of all non-consensual searches after a stop but accounted for fewer than 15% of all stops in 2015. Of all people searched without consent, Black and Hispanic people had the lowest "hit rates" (i.e., the lowest rate of contraband recovered). A 2016 Chicago Police Accountability Task Force report found that black and Hispanic drivers were searched by the Chicago Police more than four times more frequently than white drivers, but white drivers were found with contraband twice as often as black and Hispanic drivers.
Sources: en.wikipedia.org
For example, the values for glucose, sucrose, and starch are 15.57, 16.48 and 17.48 kilojoules per gram (3.72, 3.94 and 4.18 kcal/g) respectively. The differing energy density of foods (fat, alcohols, carbohydrates and proteins) lies mainly in their varying proportions of carbon, hydrogen, and oxygen atoms. Carbohydrates that are not easily absorbed, such as fibre, or lactose in lactose-intolerant individuals, contribute less food energy. Polyols (including sugar alcohols) and organic acids contribute 10 kJ/g (2.4 kcal/g) and 13 kJ/g (3.1 kcal/g) respectively. The energy contents of a food or meal can be approximated by adding the energy contents of its components, though the entire amount of calories calculated may not be absorbed during digestion.
Several methods have been proposed for PET-MRI attenuation coefficient, including machine learning, algorithms to directly estimate attenuation coefficients from the MRI or emission data, and atlas-based approaches (where the MRI scan is co-registered with a database of CT images). While attenuation-corrected images are generally more faithful representations, the correction process is itself susceptible to significant artifacts. As a result, both corrected and uncorrected images are often reconstructed and read together. 2D/3D reconstruction: Early PET scanners had only a single ring of detectors, hence the acquisition of data and subsequent reconstruction was restricted to a single transverse plane. More modern scanners now include multiple rings, essentially forming a cylinder of detectors. There are two approaches to reconstructing data from such a scanner:
Medical ultrasonography uses ultrasound (high-frequency sound waves) to visualize soft tissue structures in the body in real time. No ionizing radiation is involved, but the quality of the images obtained using ultrasound is highly dependent on the skill of the person (ultrasonographer) performing the exam and the patient's body size. Examinations of larger, overweight patients may have a decrease in image quality as their subcutaneous fat absorbs more of the sound waves. This results in fewer sound waves penetrating to organs and reflecting to the transducer, resulting in loss of information and a poorer quality image. Ultrasound is also limited by its inability to image through air pockets (lungs, bowel loops) or bone. Its use in medical imaging has developed mostly within the last 30 years. The first ultrasound images were static and two-dimensional (2D), but with modern ultrasonography, 3D reconstructions can be observed in real time, effectively becoming "4D". Because ultrasound imaging techniques do not employ ionizing radiation to generate images (unlike radiography and CT scans), they are generally considered safer and are therefore more common in obstetrical imaging. The progression of pregnancies can be thoroughly evaluated with less concern about damage from the techniques employed, allowing early detection and diagnosis of many fetal anomalies. Growth can be assessed over time, important in patients with chronic disease or pregnancy-induced disease, and in multiple pregnancies (twins, triplets, etc.).
Sources: en.wikipedia.org
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.
The synthetic peptide incorporates modifications that slow enzymatic breakdown in circulation. Native growth hormone-releasing hormone is short-lived, whereas the analog is designed for greater stability. The core amino acid backbone is largely retained.
The main studied application is reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Research has measured fat changes through imaging. Findings concern fat distribution rather than overall body weight.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.